The new study, led by researchers from Yale School of Public Health and the University of Florida, presents compelling evidence that increasing access to innovative and highly effective weight-loss medications could potentially prevent over 40,000 deaths annually in the United States. This research underscores the urgent need to dismantle the current barriers that restrict people’s access to these crucial treatments, thereby hampering public health initiatives aimed at tackling the obesity epidemic in the nation. According to statistics from the U.S. Centers for Disease Control and Prevention, approximately 74% of the American population is overweight, with about 43% falling into the obese category.

Obesity is well-known for its detrimental effects on health, significantly worsening conditions such as type 2 diabetes, cardiovascular disease, and certain forms of cancer. Despite the grave consequences associated with obesity, the development and implementation of effective obesity treatments have not kept pace with the scale of the problem. However, recent breakthroughs in pharmaceuticals, particularly with the advent of drugs like glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic and Wegovy, as well as the dual gastric inhibitory polypeptide and GLP-1 receptor agonists like tirzepatide, have proven highly effective in facilitating weight loss. These medications have performed well in clinical trials and are increasingly being prescribed for weight management.

This research aimed to estimate the mortality reduction that could be achieved by making these weight-loss drugs more accessible. The researchers combined data concerning mortality risks associated with different body mass index (BMI) levels, the prevalence of obesity, and the existing limitations on accessing these drugs, which include high costs and insurance coverage restrictions. The study revealed that if these new medications were made available to all qualifying individuals, it could result in up to 42,027 fewer deaths each year in the U.S. This figure includes around 11,769 deaths among individuals with type 2 diabetes. This group is particularly susceptible to the harmful effects of obesity. Even with the current restricted access, the study estimates that approximately 8,592 lives are saved annually, primarily among those with private health insurance.

The researchers pointed out a significant disparity in access to these drugs, primarily due to their high cost, which can exceed $1,000 per month for those without insurance. Notably, Medicare, a primary insurance provider for older adults, does not cover these medications for weight loss, significantly impacting those who stand to benefit. Medicaid coverage varies considerably across states, and private insurers often require high deductibles and co-pays, further limiting access.

Alison P. Galvani, the study’s corresponding author and the Burnett and Stender Families Professor of Epidemiology (Microbial Diseases) at Yale, emphasized that enhancing access to these medications is not merely about improving treatment options; it is a critical public health measure. The findings strongly suggest that substantial reductions in mortality could be achieved by overcoming financial and coverage obstacles.

The research also examined how broadening access to these drugs could differentially impact various regions and socioeconomic groups within the U.S. States with higher rates of obesity and diabetes, such as West Virginia, Mississippi, and Oklahoma, would likely see the most significant reductions in mortality per capita. However, the authors caution that despite the potential benefits, several significant challenges remain. The high cost of these medications poses a significant barrier, and there are concerns about pharmaceutical companies’ profit margins. Additionally, supply constraints and limitations in production capacity continue to restrict widespread availability.

Dr. Burton H. Singer, another corresponding author of the study and adjunct professor of mathematics at the Emerging Pathogens Institute at the University of Florida, highlighted that addressing these challenges necessitates a comprehensive strategy. This would involve ensuring that drug prices reflect the actual costs of manufacturing and expanding production capacity to meet demand. Concurrently, issues related to insurance coverage and accessibility must be addressed to enable more individuals to access the treatment they require.

The researchers also considered the influence of socioeconomic factors on the effectiveness of expanded access to these medications. After adjusting their estimates for income disparities, they found that the potential for saving lives remains significant. The results indicate that improving access to these drugs could reduce healthcare costs associated with obesity-related conditions and enhance many Americans’ overall quality of life.

More information: Abhishek Pandey et al, Estimating the lives that could be saved by expanded access to weight-loss drugs, Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2412872121

Journal information: Proceedings of the National Academy of Sciences Provided by Yale University